News

Study reports potential of OCT to identify vascular damage in severe COVID-19

With FDA approval, pegcetacoplan launches with high awareness—and a few questions

Why are ophthalmologists a definite maybe about biosimilars? Survey provides answers

A deeper dive into anti-VEGF loss to follow-up: Study identifies risk factors

Where are the women in retina? Not at the podium, study reports

Bevacizumab first, aflibercept second cost-effective for DME, Protocol AC finds

With Byooviz, Biogen takes a leap on pricing first U.S. retina biosimilar

New DME treatment trial targets underrepresented populations

A deeper dive into why DAZZLE results of KSI-301 in nAMD ‘disappointed’

Retina Update: Is Vabysmo the next $1 billion anti-VEGF?

Load More